Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.017
Neutral
RSI(14)
42.009
Neutral
STOCH(KDJ)(9,3,3)
46.987
Buy
ATR(14)
0.621
Low Volatility
CCI(14)
-49.294
Neutral
Williams %R
64.507
Sell
TRIX(12,20)
-0.667
Sell
StochRSI(14)
68.531
Sell
ARS Pharmaceuticals Inc
SPRY8.070USD
0.0000.00%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
266.85MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of ARS Pharmaceuticals Inc
Currency: USD Updated: 2026-03-27Key Insights
ARS Pharmaceuticals Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 49 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 26.67.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ARS Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
ARS Pharmaceuticals Inc Highlights
StrengthsRisks
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 280826.67% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 84.28M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 84.28M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is -4.64, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 88.21M shares, decreasing 10.51% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 3.50M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.06.
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
26.667
Target Price
+211.53%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of ARS Pharmaceuticals Inc is 6.78, ranking 203 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 28.09M, representing a year-over-year decrease of 67.56%, while its net profit experienced a year-over-year decrease of 182.76%.
Score
Financials
5.03
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.23
Operational Efficiency
3.15
Growth Potential
9.97
Shareholder Returns
7.50
ARS Pharmaceuticals Inc's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of ARS Pharmaceuticals Inc is 6.91, ranking 200 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -4.64, which is -3983.66% below the recent high of 180.34 and -2397.53% above the recent low of -115.98.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 49/391
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of ARS Pharmaceuticals Inc is 9.33, ranking 6 out of 391 in the Biotechnology & Medical Research industry. The average price target is 31.00, with a high of 35.00 and a low of 12.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
26.667
Target Price
+211.53%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
548
Total
6
Median
6
Average
Company name
Ratings
Analysts
ARS Pharmaceuticals Inc
SPRY
6
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
27
argenx SE
ARGX
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
110
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of ARS Pharmaceuticals Inc is 7.24, ranking 64 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 9.41 and the support level at 6.96, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
7.948
Buy
MA10
8.205
Sell
MA20
8.512
Sell
MA50
9.311
Sell
MA100
9.592
Sell
MA200
11.599
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of ARS Pharmaceuticals Inc is 7.00, ranking 85 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 89.24%, representing a quarter-over-quarter increase of 0.52%. The largest institutional shareholder is The Vanguard, holding a total of 3.50M shares, representing 3.52% of shares outstanding, with 0.58% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of ARS Pharmaceuticals Inc is 4.29, ranking 91 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.83. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.85
VaR
+6.84%
240-Day Maximum Drawdown
+63.32%
240-Day Volatility
+66.89%
Return
Best Daily Return
60 days
+19.27%
120 days
+19.27%
5 years
+77.88%
Worst Daily Return
60 days
-12.86%
120 days
-12.86%
5 years
-55.79%
Sharpe Ratio
60 days
-1.88
120 days
-0.30
5 years
+0.04
Risk Assessment
Maximum Drawdown
240 days
+63.32%
3 years
+67.88%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
-0.67
3 years
+0.00
5 years
-0.15
Skewness
240 days
+0.51
3 years
+2.81
5 years
+1.95
Volatility
Realised Volatility
240 days
+66.89%
5 years
--
Standardised True Range
240 days
+8.79%
5 years
+8.16%
Downside Risk-Adjusted Return
120 days
-51.60%
240 days
-51.60%
Maximum Daily Upside Volatility
60 days
+51.50%
Maximum Daily Downside Volatility
60 days
+53.67%
Liquidity
Average Turnover Rate
60 days
+1.72%
120 days
+1.74%
5 years
--
Turnover Deviation
20 days
+106.29%
60 days
+54.61%
120 days
+56.57%
Peer Comparison
Biotechnology & Medical Research
ARS Pharmaceuticals Inc
SPRY
7.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Day One Biopharmaceuticals Inc
DAWN
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
